July 11, 2017 1pm - 2pm EDT
A panel of B&P patent experts will give you a point-by-point analysis of the greatly anticipated decision of the Supreme Court of Canada in Astrazeneca v. Apotex, was handed down on June 30th. The Supreme Court provided new insights and direction to the Canadian patent law of utility and "the promise of the patent". Our panel will discuss the implications of the decision on patent drafting, prosecution and litigation.
This program may be counted towards 1.0 substantive hours in Ontario.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
